Title

RNA toxicity and perturbation of rRNA processing in spinocerebellar ataxia type 2

Authors:

Pan P. Li, Ph.D.^{1*}, Roumita Moulick, Ph.D.^{2#}, Hongxuan Feng, Ph.D.^{1#}, Xin Sun, Ph.D.¹, Nicolas Arbez, Ph.D.¹, Jing Jin, M.D., Ph.D.¹, Leonard O. Marque, B.S.¹, Erin Hedglen, M.A.¹, H.Y. Edwin Chan, Ph.D.³, Christopher A. Ross, M.D., Ph.D.^{1,4,5}, Stefan M. Pulst, M.D.⁶, Russell L. Margolis, M.D.^{1,4}, Sarah Woodson, Ph.D.², Dobrila D. Rudnicki, Ph.D.¹

Addresses:

¹Department of Psychiatry and Behavioral Sciences, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

²T.C. Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA

³Biochemistry Program, School of Life Sciences, The Chinese University of Hong Kong, Hong Kong

⁴Department of Neurology, and ⁵Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

⁶Department of Neurology, University of Utah, Salt Lake City, Utah, USA

#equal contribution

*Corresponding Author

Pan P. Li

Department of Psychiatry and Behavioral Sciences, Division of Neurobiology, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, USA

Telephone: +1 4105023760; Fax: +1 4106140013; Email: ple5@jhmi.edu

Word count: 3667 words (excluding abstract and figure legends)

Relevant conflict of interest/financial disclosure: Nothing to report.

Funding agencies: This work was supported by the National Institutes of Health grants NS064138 (to D.D.R.), NS112796 (to P.P.L.), NS112687 (to P.P.L.), NS099397 (to S.W.), and NS033123 (to S.M.P.).

Abstract

BACKGROUND:

Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disease caused by expansion of a CAG repeat in *Ataxin-2* (*ATXN2*) gene. The mutant ATXN2 protein with a polyglutamine tract is known to be toxic and contributes to the SCA2 pathogenesis.

OBJECTIVE:

Here we tested the hypothesis that the mutant *ATXN2* transcript with an expanded CAG repeat (*expATXN2*) is also toxic and contributes to SCA2 pathogenesis.

METHODS:

The toxic effect of *expATXN2* transcripts on SK-N-MC neuroblastoma cells and primary mouse cortical neurons was evaluated by caspase 3/7 activity and nuclear condensation assay, respectively. RNA immunoprecipitation assay was performed to identify RNA binding proteins (RBPs) that bind to *expATXN2* RNA. Quantitative PCR was used to examine if rRNA processing is disrupted in SCA2 and Huntington disease (HD) human brain tissue.

RESULTS:

expATXN2 RNA induces neuronal cell death, and aberrantly interacts with RBPs involved in RNA metabolism. One of the RBPs, transducin β -like protein 3 (TBL3), involved in rRNA processing, binds to both *expATXN2* and expanded *huntingtin* (*expHTT*) RNA *in vitro*. rRNA processing is disrupted in both SCA2 and HD human brain tissue.

CONCLUSION:

These findings provide the first evidence of a contributory role of *expATXN2* transcripts in SCA2 pathogenesis, and further support the role *expHTT* transcripts in HD pathogenesis. The disruption of rRNA processing, mediated by aberrant interaction of RBPs with *expATXN2* and

expHTT transcripts, suggest a point of convergence in the pathogeneses of repeat expansion diseases with potential therapeutic implications.

Introduction

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant disorder caused by a CAG repeat expansion in the first exon of the *ATXN2* gene located on chromosome 12q24¹. The repeat is in-frame to encode polyglutamine (polyQ). The signs and symptoms of SCA2 include progressive deterioration in balance and coordination, neuropathies, nystagmus and slow saccadic eye movements, slurred speech and cognitive impairment²⁻⁵. SCA2 is the second most common form of autosomal dominant ataxia, with a prevalence of 1-2 cases/10⁵ inhabitants, varying somewhat by ethnicity and geographic location^{2, 3, 6-8}. The highest prevalence of the SCA2 mutation occurs in Cuba (6.57 cases/10⁵ inhabitants)⁹, and is likely a consequence of a founder effect¹⁰. SCA2 neuropathology is characterized by a significant loss of cerebellar Purkinje neurons, a less prominent loss of cerebellar granule cells¹¹; marked neuronal loss in the inferior olive, pontocerebellar nuclei, and substantia nigra; degeneration of the thalamus and pons, and thinning of the cerebellar cortex without changes in neuronal density¹¹⁻¹⁴. The normal *ATXN2* allele contains 15 to 32 CAG triplets, while the disease allele typically has 33 to 64 triplets¹⁵. The most common disease allele has 37 triplets, and neonatal onset SCA2 cases with over 200 CAG repeats have been reported¹⁶. Similar to other CAG repeat diseases, the repeat length in SCA2 is inversely correlated to age of onset^{17, 18}. Recently, intermediate CAG expansion in *ATXN2* has been associated with a higher risk for amyotrophic lateral sclerosis (ALS)¹⁹. Current evidence indicates that neurotoxicity of *ATXN2* protein, which is involved in multiple cellular pathways, including mRNA maturation, translation, and endocytosis, is central to SCA2 pathogenesis^{20, 21}. This is supported by data from several SCA2 cell and mouse models expressing mutant *ATXN2* protein²²⁻²⁴.

However, multiple laboratories, including ours, have demonstrated an important neurotoxic role for mutant RNA transcripts in CAG/CTG repeat expansion diseases, including myotonic dystrophy type 1 (DM1)^{25, 26}, Huntington disease (HD)^{27, 28}, Huntington disease-like 2 (HDL2)²⁹, SCA3³⁰⁻³², and SCA8³³. RNA-triggered pathogenic processes are thought to be, at least in part, mediated by aberrant interaction between expanded repeat-containing RNA transcripts and RNA-binding proteins (RBPs)³⁴⁻³⁶. The basic hypothesis is that expanded CAG/CUG repeats in transcripts form hairpin structures which sequester multiple RBPs and hence prevent the RBPs from performing their normal function in cells³⁵. To add to the pathomechanistic complexity of CAG/CUG repeat diseases, antisense transcripts that span the CAG/CUG repeat regions are also expressed at the DM1 (CAG direction)³⁷, HDL2 (CAG direction)^{38, 39}, SCA7 (CUG direction)⁴⁰, SCA8 (CUG direction)³³ and HD (CUG direction)⁴¹ loci. We have recently described a transcript expressed antisense to *ATXN2* at the SCA2 locus⁴², and provided evidence that this antisense *ATXN2* (*ATXN2*-AS) transcript contributes to SCA2 pathogenesis, and potentially to ALS associated with an intermediate repeat expansion at the *ATXN2* locus¹⁹. We hypothesized that, in addition to mutant *ATXN2* protein and mutant *ATXN2*-AS transcript⁴², mutant sense *ATXN2* RNA also contributes to SCA2 pathogenesis.

As predicted by this hypothesis, the data presented here demonstrate that sense *expATXN2* transcripts are neurotoxic in cell models in the absence of expression of mutant *ATXN2* protein, aberrantly interact with RBPs that are involved in rRNA processing, and lead to disruption of rRNA processing. We demonstrate a similar disruption of rRNA processing in HD patient brain tissue. Similar to findings in other repeat expansion diseases, SCA2 is therefore the fifth neurodegenerative CAG/CTG repeat expansion disease in which pathogenesis is likely a consequence of a combination of expression of mutant protein and bi-directionally expressed mutant RNA.

Materials and Methods

Description of materials and methods is provided in the supplementary data.

Results

The non-translatable expATXN2 transcript is neurotoxic

To confirm the toxicity of *expATXN2* transcripts, we cloned FL *ATXN2* cDNA with 22, 58, or 104 CAG triplets into the 3' untranslated (UTR) region of *Renilla luciferase (Rluc)* cDNA, thereby allowing expression of *expATXN2* RNA transcripts, but preventing ATG-initiated translation of the RNA into FL *ATXN2* protein (Fig. 1A). No evidence of expression of an expanded polyglutamine tract was detected by Western blotting using the expanded polyglutamine-specific antibody 1C2⁴³, confirming that the 3' UTR cloning approach indeed eliminated detectable ATG-initiated translation of the FL *ATXN2* (Fig. 1B). Caspase 3/7 activity assay showed that overexpression of *Rluc-ATXN2-(CAG)58* or *Rluc-ATXN2-(CAG)104* was significantly more toxic than *Rluc-ATXN2-(CAG)22* in SK-N-MC cells (Fig. 1C). Comparable expression levels of overexpressed transcripts in SK-N-MC cells were confirmed by qPCR (Fig. 1D). However, hairpin-forming expanded CAG repeats can also be translated in the absence of ATG start codon through the mechanism of repeat-associated non-ATG translation (RAN translation)⁴⁴. To exclude the possibility that RAN translation of protein fragments with expanded amino acid tracts leads to neurotoxicity in our SK-N-MC model system, we cloned an *ATXN2* fragment containing a CAG repeat expansion, multiple upstream stop codons, and 150 bp of *ATXN2* sequence flanking the repeat (thereby excluding all ATGs) into a vector with tags for each of the three open reading frames (Fig. S1A). There were no detectable protein fragments from any of the three reading frames (Fig. S1B-E), indicating that SK-N-MC cells do not support the RAN translation of *expATXN2* transcripts, and confirming that expression of FL *expATXN2* transcript is sufficient to trigger neurotoxicity even when the transcripts are not translated into proteins. Consistent with these observations in neuroblastoma cells, overexpression of *Rluc-ATXN2-(CAG)104* triggers neurotoxicity in primary mouse cortical neurons, as measured by nuclear

condensation assay (Fig. 1E). *Rluc-ATXN2-(CAG)58* was not toxic in this assay, perhaps reflective of the short time frame of the experiment (nuclear condensation is a later stage event, whereas caspase 3/7 activation occurs at an early stage in cell death), differences in the levels of transcript expression in primary neurons compared to neuroblastoma cell lines, or different sensitivity to transcript-induced toxicity in primary neurons and SK-N-MC cells.

It has been suggested that the CAG repeats form stable hairpin structures³⁵, while CAA interruptions either break hairpin regularity or induce the formation of branched structures⁴⁵. To examine whether preventing the formation of hairpin structures in *expATXN2* ameliorate its neurotoxicity, we replaced the pure CAG repeat region in the *ATXN2-(CAG)104* with a fragment of heavily interrupted CAG/CAA triplets, to obtain the *ATXN2-(CAG/CAA)105* construct. Inserting interruptions abolished *expATXN2* toxicity in primary mouse cortical neurons (Fig. 1F), suggesting that the secondary hairpin structure adopted by the pure CAG repeat may be critical for neurotoxicity.

Full-length expATXN2 transcripts form RNA foci in SCA2 cell and mouse models, and in one human SCA2 brain.

Repeat-containing mutant transcripts form RNA foci in all CUG/CAG diseases in which RNA neurotoxicity has been demonstrated to contribute to pathogenesis⁴⁶⁻⁴⁸. We therefore sought to detect similar foci in SCA2 models and human brain by fluorescence *in situ* hybridization (FISH). CAG RNA foci were absent in SK-N-MC neuroblastoma cells that overexpress *GFP* alone (Fig. 2A) or a FL ATXN2 construct modified to have only one CAG triplet (*GFP-ATXN2Q1*, Fig. 2B), and were only rarely detected in cells overexpressing FL normal *ATXN2* (*nATXN2*) transcripts with 22 triplets (*GFP-ATXN2Q22*, Fig. 2C). Foci were much more abundant in cells overexpressing full-length (FL) expanded *ATXN2* (*expATXN2*) transcripts with 58 or 104 CAG triplets (*GFP-ATXN2Q58* or *GFP-ATXN2Q104*, Fig. 2D and 2F), as quantified in Fig. 2E. The foci are resistant to DNase treatment and are degraded by RNase treatment (Fig. 2G and 2H).

This set of experiments demonstrates that *expATXN2* transcripts form RNA foci, and that the extent of foci formation may at least partially correlate with repeat length. Furthermore, while not detected in wildtype (WT, Fig. 2I-J) mice, *ATXN2* RNA foci are present in cerebellar Purkinje neurons of SCA2 transgenic mice (Fig. 2K-L) which express FL *ATXN2* with 127 CAG triplets specifically in Purkinje neurons²². Finally, out of the five human postmortem brains available for this study, *ATXN2* RNA foci were detected in cerebellar Purkinje cells in one brain (H1 case, Table 1) that had 38 triplets for the mutant allele (Fig. 2O-P), but not in the control human brains (Fig. 2M-N). RNA foci may be only a hallmark for RNA toxicity, and whether RNA foci are toxic or not remains to be further determined.

expATXN2 transcripts aberrantly interact with RNA binding proteins (RBPs)

We next examined whether the neurotoxicity of *expATXN2* transcript is mediated by aberrant *expATXN2* RNA-RBP interactions. We performed an *in vitro* biotinylated *ATXN2* RNA pull-down assay (Fig. 3A) and identified by mass spectrometry (MS) a total of 57 RBPs that preferentially bind to the *expATXN2*, compared to the *nATXN2* transcript. GO analysis of functional annotation⁴⁹ and STRING analysis⁵⁰ of the *expATXN2* RBPs are shown in Fig. S2. A selective list of *expATXN2* RBPs is shown in Table S1. Out of the 57 *expATXN2* RBPs, 40 are localized in the nucleus, with 20 of them in the nucleolus, suggesting that aberrant *expATXN2*-RBP interactions may predominantly occur in the nucleus. Interestingly, among the 20 nucleolar RBPs, 7 of them contain WD40 repeat domains, of which, five (PWP1, TBL3, WDR3, WDR36 and UTP18; Table S1 and Fig. S2B) are components of the small subunit (SSU) processome for ribosomal RNA (rRNA) processing. We therefore became interested in the SSU processome components that were identified as *expATXN2* RBPs. Out of the five SSU components^{51, 52} that are potential *expATXN2* interactors, we selected TBL3 (transducin β -like protein 3) for further analysis, as we were interested in RNA mediated disease mechanisms shared by both SCA2 and HD, and by the same method, TBL3 appeared to interact with the expanded *Huntingtin*

(*expHTT*) transcript as well (Fig. 3B-C), and has a relatively greater number of peptide hits and percentage of protein coverage, compared with other SSU components identified by MS (Table S1), though the number of peptide hits does not always imply stronger interaction⁵³.

TBL3 binds to expanded CAG repeats in vitro

We performed additional RNA pull down experiments and western blots to confirm that TBL3 interacts with *expATXN2 in vitro* (Fig. 3B). To test whether the interaction is disease-specific, we also included *expHTT* transcripts, associated with HD, the most prevalent and most studied CAG repeat disease^{27, 28, 41, 54}. Studies from multiple laboratories, including ours, support the idea that RNA neurotoxicity contributes to HD^{27-29, 47}. We confirmed that TBL3 interacts *in vitro* with expanded CAG repeats flanked with either *ATXN2* or *HTT*-specific sequence (Fig. 3B), but not with expanded CUG repeats flanked with either antisense *ATXN2* (*ATXN2-AS*;⁴²), antisense *HTT* (*HTT-AS*; expressed on HD locus)⁴¹, or junctophilin-3 (*JPH3*) flanking sequence²⁹ (Fig. 3B). To further confirm that the interaction between TBL3 and *expATXN2* and *expHTT* was dependent on the CAG repeat, we pre-incubated *expATXN2* and *expHTT* transcripts with (CTG)₈C Morpholino (MO), which we have previously established hybridizes to CAG repeat expansions⁵⁵. The pretreatment with (CTG)₈C prevented TBL3 from binding to either transcript *in vitro* and provided further evidence that both *expATXN2*-TBL3 and *expHTT*-TBL3 interactions are dependent on the presence of an expanded CAG repeat (Fig. 3C). Taken together, these data indicate that TBL3 binds to expanded CAG repeats independent of flanking sequence.

To investigate whether TBL3 binds to expanded CAG repeats independently of other cellular proteins, we purified the TBL3 N-terminal RNA binding domain as a fusion with maltose binding protein (MBP-NTD-TBL3) and measured its binding with *expATXN2* transcripts using an *in vitro* nitrocellulose filter binding assay⁵⁶. The isolated TBL3 NTD associated with *ATXN2* CAG RNA, with $K_D = 350$ nM and 420 nM for *ATXN2*-(CAG)₂₂ and *ATXN2*-(CAG)₁₀₈, respectively (Fig. 3D). Although overall binding was weak, the yeast homolog of TBL3, Utp13, binds pre-rRNA as

a tetramer with other UtpB complex proteins. Therefore, the weak affinity of the isolated MBP-NTD-TLB3 for *expATXN2* may be due to the absence of its normal binding partners. The *in vitro* binding reactions saturated approximately 20-30% of refolded *ATXN2* RNA, suggesting that a fraction of the *ATXN2* RNA is unable to refold into a conformation that is competent to bind TBL3.

Despite its weak affinity for RNA, MBP-NTD-TBL3 bound *ATXN2* CAG repeats more strongly than control RNAs, including the *ATXN2*-AS-(*CUG*)₁₁₀ transcript ($K_D=650$ nM), and a CAG repeat containing CAA interruptions, *ATXN2*-(*CAG/CAA*)₁₀₅ ($K_D=2.1$ μ M). This preference for continuous CAG repeats raised the possibility that TBL3 recognizes the hairpin structure of CAG repeat RNA. To test this idea, the filter binding assays were also carried out in the presence of a competitor yeast tRNA, which is expected to be structured under our assay conditions. The tRNA competitor abolished the interaction between MBP-NTD-TBL3 and *ATXN2* or *ATXN2*-AS transcripts (Fig. 3D), consistent with the idea that TBL3 binding depends on the structures of *ATXN2* CAG repeats.

The effect of TBL3 reduction on 45S pre-rRNA level and processing

Depletion of UTP13, the yeast homolog of TBL3, increases the steady-state level of unprocessed 35S pre-rRNA in yeast⁵⁷. We therefore hypothesized that, although the interaction between *expATXN2* and TBL3 may not be direct and likely involves other proteins, sequestration of TBL3 in a complex that interacts with *expATXN2* may disrupt its normal function and affect rRNA maturation. We therefore predicted that knockdown of TBL3 in cells, mimicking its sequestration, would increase the level of unprocessed 45S pre-rRNA, the human counterpart of yeast 35S pre-rRNA. Three individual siRNAs were used to knock down TBL3 in HEK293T cells in order to minimize the possibility of alternative mechanisms of TBL3 reductions through off-target effects. Each siRNA reduced TBL3 protein level by 50-80% at 72 hours post transfection (Fig. 4A-B). Next, we examined 45S pre-rRNA levels by qPCR using primers

against the 5' external transcribed spacer⁵⁸ as indicated in Fig. 4C. Knockdown of TBL3 in HEK293T cells using each siRNA increased steady-state 45S pre-rRNA levels (normalized to *ACTB*, Fig. 4D), consistent with a previous study using stable shRNA transfection⁵⁹. As previously reviewed^{60, 61}, a complex sequence of cleavage steps is required to release the mature RNAs (18S, 5.8S and 28S) from the precursor 45S pre-rRNA. qPCR using primers against 18S rRNA would detect the mature 18S rRNA, unprocessed 45S pre-rRNA, as well as any intermediate rRNAs containing 18S sequence. Similarly, qPCR using primers against 28S rRNA would detect the mature 28S rRNA, the 45S pre-rRNA precursor, as well as intermediate rRNAs that contain the 28S sequence (Fig. 4C). We therefore used the ratios of 18S rRNA/45S pre-rRNA and 28S rRNA/45S rRNA measured by qPCR, as readouts for 18S rRNA maturation and 28S rRNA maturation, respectively. Depletion of UTP13 in yeast has been previously shown to decrease 18S rRNA maturation^{62, 63}. Consistently, we found that knock down of TBL3 in HEK293T cells decreased the ratio of 18S rRNA to 45S pre-rRNA (Fig. 4E), indicating that TBL3 may play a role in 18S rRNA maturation. In addition, 28S rRNA maturation was also decreased after TBL3 knock down (Fig. 4F). We attempted to determine if overexpression of TBL3 has the opposite effect, however, forced expression of TBL3 by itself triggered toxicity and mis-localized the protein into nuclear aggregates (data not shown). Similarly, MBNL1, an RBP previously shown to interact with expanded CAG/CUG (*expCAG/CUG*) transcript also appeared to be toxic when overexpressed or knocked down²⁸, suggesting that expression of certain RBPs must be tightly controlled to maintain their normal function.

45S pre-rRNA level and processing is altered in SCA2 and HD postmortem tissue

Finally, we examined the expression of 45S pre-rRNA in human postmortem SCA2 and HD cerebella. qPCR amplification suggested that there was a slight, though not statistically significant, increase of 45S pre-rRNA level (normalized to *ACTB*) in both SCA2 and HD cerebella, compared with control (Fig. 4G). The qPCR results suggested that there was a

decrease in both 18S rRNA maturation and 28S rRNA maturation in SCA2 and HD cerebella, compared with the controls (Fig. 4H-I), consistent with the trend observed with the knock down of TBL3 (Fig. 4D-F). Only the decrease in HD samples, but not in SCA2 samples, reached statistical significance, under the caveat that the relatively lower statistical power in SCA2 samples may not allow the detection of small changes. Taken together, the data supports the idea that aberrant RNA-RBP interactions may affect the steady state level and the maturation of 45S pre-rRNA in both SCA2 and HD.

Discussion

We have previously shown that antisense *ATXN2-AS* transcripts contribute to SCA2 pathogenesis⁴². Here we provide the first evidence that sense *expATXN2* transcripts is involved in SCA2 pathogenesis. First, in establishing its potential pathogenicity, we show that untranslatable FL *ATXN2* transcript is neurotoxic (Fig. 1). This model is not suitable to test the contribution of sense *ATXN2* transcript relative to the toxicity of *ATXN2* protein, or antisense *ATXN2-AS* RNA⁴², because neither *ATXN2* protein nor *ATXN2-AS* RNA is present in this model. In the future, genome editing approaches can be used to establish SCA2 iPS cell models that specifically model protein- versus RNA-triggered mechanism of pathogenesis. SCA2 iPSCs can also be subjected to transcriptome, proteome, and RNA interactome analysis to identify additional pathways that are involved in RNA-mediated aspects of SCA2 pathogenesis. Differentiation into neuronal types of greater and lesser selective vulnerability in SCA2 (e.g., Purkinje cells, cortical excitatory neurons, etc.) could be used to determine cell type vulnerability to RNA and protein mediated neurotoxicity. Next, we show that the *expATXN2* transcripts aggregate into nuclear RNA foci in SCA2 cell and transgenic mouse models, as well as in human SCA2 postmortem brain tissue. However, out of five human SCA2 postmortem brains available for this study, *expATXN2* RNA foci were only detected in case H1 that had the 22/38 *ATXN2* CAG repeat lengths and the latest disease on-set (Table 1). Interestingly, we

have recently characterized a transcript that is expressed in the direction antisense to *ATXN2* (*ATXN2-AS*) and contains an expanded CUG repeat⁴². CUG RNA foci containing this transcript were detected in SCA2 cases K3 and M1 (Table 1; ⁴²). Given that SCA2 is associated with a relatively short repeat expansion, detection of foci may require a more sensitive assay. There are a number of alternative explanations for the absence of foci in the other SCA2 brains: (1) CAG RNA foci are highly toxic, or appear in cells marked for early death, such that Purkinje cells with foci may not have been present by the time of death; (2) CAG RNA foci are protective and associated with late onset disease and perhaps slower disease progression; (3) detectable foci were lost consequent to the process of brain collection or storage; (4) RNA foci are a byproduct of neurotoxic processes and have a neutral role in neurotoxicity; 5) RNA foci are an epiphenomenon, present in some SCA2 brains because of an unknown genetic or environmental factor and with no relevance to disease. Recent work describing a transgenic BAC mouse model expressing expanded *C9orf72* (*expC9orf72*) and exhibiting widespread RNA foci, but lacking behavioral abnormalities and neurodegeneration, even at advanced ages, suggests that RNA foci are not sufficient to trigger toxicity in ALS⁶⁴. A transgenic mouse model expressing non-translatable FL *ATXN2*, which could be tracked in live cells in real time⁶⁵ might help determine the relevance of CAG RNA foci to disease pathogenesis.

Our data strongly suggests that the neurotoxicity of *expATXN2* transcript involves aberrant *expATXN2*-RBP interactions that perturb rRNA maturation. We initially focused on Transducin beta like protein 3 (TBL3), a component of the SSU processome required for rRNA processing. While our RNA pull-down assay indicates that TBL3 interacts with *expATXN2* RNA, this assay cannot be used to prove a direct interaction. Filter-binding assays showed that recombinant TBL3 NTD can weakly interact with *expATXN2* RNA, and preferentially binds the structures of the CAG repeats. (Fig. 3D). Other components of the SSU processome likely stabilize the interaction of TBL3 with the *expATXN2* RNA in the cell. The yeast homolog of TBL3, Utp13,

recognizes double-stranded regions of the pre-rRNA as a heterotetramer with other Utp proteins. Indeed, mass spectrometry analysis of *expATXN2* interactors did identify other proteins from the SSU processome in our isolated complexes (Table S1). One interesting possibility is that the multi-dentate recognition of structured RNA by TBL3 and its binding partners, which is a normal feature of their function in pre-rRNA processing, also contributes to the toxic aggregation of CAG repeat RNAs. Future experiments will be needed to determine which proteins are most important for neuronal toxicity.

Our results indicate that a subset of RBPs bind to both expanded *ATXN2* and *HTT* transcripts. This is not surprising, as it is well established that transcripts containing expanded CAG repeats form similar secondary structures *in vitro*^{35, 66, 67} and, hence, at least some of the downstream effects are likely to be shared between different CAG repeat diseases. While SCA2 primarily affects cerebellum, HD is primarily characterized by atrophy of striatum and cerebral cortex⁶⁸. However, recent evidence indicates that cerebellum is also affected in HD^{69, 70} and, in fact, appears to degenerate early⁷¹ and independently from the striatal atrophy⁷¹. This suggests that similar mechanism of pathogenesis may contribute to cerebellar pathology in both SCA2 and HD. Whether and to which degree mutant RNA-triggered mechanisms contribute to this pathology, remain to be further determined.

Interestingly, it was previously reported that expanded *ataxin-3* (*ATXN3*) transcripts, involved in spinocerebellar ataxia type 3 (SCA3) interact with nucleolin. In SCA3, this aberrant nucleolin-*ATXN3* interaction decreases 45S pre-rRNA levels in cell and *Drosophila* models of SCA3³¹. On the other hand, aberrant interaction between the *expC9orf72* transcripts and nucleolin, may contribute to the decreased maturation of 28S, 18S and 5.8S rRNAs from the precursor 45S pre-rRNA in ALS patients associated with CCCCCG hexamer expansion in *C9orf72* gene⁷². It is quite possible that a therapeutic agent that prevents aberrant RNA-RBP interactions between toxic hairpin-forming transcripts and RBPs may be at least partially effective across multiple

diseases. Alternatively, similar therapies may target shared pathogenic pathways downstream of the toxic transcripts.

In summary, we provide the first evidence that the *ATXN2* transcript with an expanded repeat may contribute to SCA2 pathogenesis, with similar properties to transcript-mediated toxicity in HD. The *ATXN2* transcript with an expanded CAG repeat itself, or its protein interactors, may provide valuable therapeutic targets in the future.

Figure legends

Fig. 1. Non-translatable full length *expATXN2* transcript is neurotoxic to SK-N-MC cells. (A) Schematic presentation of the non-translatable full length (FL) *ATXN2* cell model. FL *ATXN2* cDNA was cloned into 3' UTR region of Renilla luciferase (*Rluc*) cDNA to prevent its translation. (B) *Rluc-ATXN2-(CAG)_n* constructs does not express canonically or RAN translated polyglutamine (polyQ), as confirmed by immunoblotting with polyQ-specific 1C2 antibody. β -actin was used as a loading control. A representative blot was shown. (C) At 72 hours after overexpression, both *Rlu-ATXN2-(CAG)₅₈* and *Rluc-ATXN2-(CAG)₁₀₄* transcripts are toxic to neuronal-like SK-N-MC cells, as determined by Caspase 3/7 activity assay. The Caspase 3/7 activity in *Rluc-ATXN2-(CAG)₂₂* transfected SK-N-MC cells was normalized to 100. Data were expressed as mean $\pm$ SEM from 4 independent samples per condition (N=4); **p<0.01 by Kruskal–Wallis test and Dunn's multiple comparison test. (D) Comparable expression levels of exogenous *Rluc-ATXN2-(CAG)_n* transcripts were confirmed by qPCR. *ACTB* transcript was used as an internal control. Locations of qPCR primers for *Rluc* were indicated in A. The *Rluc/ACTB* ratio in *Rluc-ATXN2-(CAG)₂₂* transfected SK-N-MC cells was normalized to 1. Data were expressed as mean $\pm$ SEM from 4 independent samples per condition (N=4); Kruskal–Wallis test. (E) At 48 h after overexpression, *Rluc-ATXN2-(CAG)₁₀₄* is toxic to primary mouse cortical neurons, as determined by a nuclear condensation assay. (F) *expATXN2* transcript toxicity depends on the repeat's ability to form toxic hairpin structures. *ATXN2-(CAG)₁₀₄*, but

not the interrupted *ATXN2*-(CAG/CAA)₁₀₅, is toxic to primary mouse cortical neurons, as indicated by a nuclear condensation assay. Data are expressed as mean $\pm$ SEM from 4-8 independent samples per condition (N=4-8). In each sample, 4,000 neurons per condition were analyzed. * $p < 0.05$, ** $p < 0.01$ by Kruskal–Wallis test and Dunn’s multiple comparison test.

Fig. 2. *expATXN2* transcripts form RNA foci. (A-H) Exogenous *expATXN2*-AS transcripts form nuclear CAG RNA foci in SK-N-MC neuroblastoma cells. *GFP-ATXN2*-(CAG)₅₈ or ₁₀₄ (D and F) transcripts formed frequent foci, while RNA foci were occasionally detected in *GFP-ATXN2*-(CAG)₂₂ expressing cells (C) and were absent in cells expressing GFP (A) or *GFP-ATXN2*-(CAG)₁ (B). (E) The percentage of cells with foci. Data were expressed as mean $\pm$ SEM from 3 independent samples per condition (N=3); * $p < 0.05$ by Kruskal–Wallis test and Dunn’s multiple comparison test, compared to *GFP-ATXN2*-(CAG)₂₂. (G-H) *GFP-ATXN2*-(CAG)₁₀₄ RNA foci were resistant to DNase treatment (G) and degraded by RNase treatment (H). (I-L) *expATXN2* transcript forms RNA foci in the cerebellar Purkinje cells of SCA2 transgenic (Tg) mice in which the expression of FL *ATXN2*-Q127 cDNA is driven by a Purkinje cell specific *Pcp2* promoter²⁴ (K-L). RNA foci were not detected in wildtype control mice (I-J). (M-P) *expATXN2* transcript forms RNA foci in cerebellar Purkinje cells of a human SCA2 brain (O-P), but not in human control cerebella (M-N). Scale bar: 5 μ m. Arrows point to RNA foci and asterisks indicate the Purkinje cells.

Fig. 3. TBL3 aberrantly interacts with *expATXN2* and *expHTT* transcripts. (A) Schematic illustration of the biotinylated RNA pull-down procedure. (C) TBL3 interacts with biotinylated *expATXN2* (with 58 or 104 CAG repeats) and *expHTT* (with 56 or 80 CAG repeats) RNAs in an *in vitro* biotinylated RNA pull-down assay. The interaction of TBL3 is specific for expanded CAG repeats, as no binding between TBL3 and CUG repeats in *JPH3*-(CUG)₅₅, *ATXN2*-AS-(CUG)₁₀₄ or *HTT*-AS-(CUG)₈₀ was observed. (D) Interaction between TBL3 and *expATXN2* or *expHTT* is dependent on the CAG repeat region. Incubation with (CTG)₈C, but not control

Morpholino (MO), abolished the binding of TBL3 to *ATXN2*-(CAG)¹⁰⁴ or *HTT*-(CAG)⁸⁰ transcript. SK-N-MC cell lysate was used as a positive control. N=3 independent experiments and representative blots were shown. (E) Nitrocellulose filter-binding analysis of MBP-NTD-TBL3 binding to *ATXN2*-(CAG)²², ¹⁰⁸, *ATXN2*-(CAG/CAA)¹⁰⁵, and *ATXN2*-AS-(CUG)¹¹⁰ RNAs. The circles represent the mean fraction RNA bound to MBP-NTD-TBL3 in the absence or presence of competitor tRNA (w tRNA), respectively. Schematic presentation of the transcripts with various repeats and lengths of flanking regions are shown. Mean and SEM are shown; n ≥ 3 independent trials. The fits through the data are from non-linear regression analysis of the binding curves to a Scatchard plot. In the absence of competitor tRNA, the K_D obtained for *ATXN2*-(CAG)²², *ATXN2*-(CAG)¹⁰⁸, *ATXN2*-(CAG/CAA)¹⁰⁵, and *ATXN2*-AS-(CUG)¹¹⁰ were 350 nM, 420 nM, 2.1 μM and 650 nM respectively.

Fig. 4. rRNA processing is affected in TBL3 knock-down cells, as well as in SCA2 and HD brains. (A-B) siRNAs against TBL3 (siTBL3), but not control siRNAs (siCtl), efficiently knocked down TBL3 protein expression by 50-80% in HEK293T cells after 72 hours. Representative blots were shown. TBL3/β-actin protein expression in siCtl treated cells was normalized to 100. Data were expressed as mean ± SEM from 3 independent samples per condition (N=3). *p < 0.05 and **p<0.01 by Kruskal–Wallis test and Dunn’s multiple comparison test. (C) Locations for qPCR primers for the detection of 45S pre-rRNA, 18S rRNA and 28S rRNA. (D-F) TBL3 knock down increased 45S pre-rRNA/ACTB ratio but decreased 18S rRNA/45S pre-rRNA ratio, compared to siCtl treated cells. 45S pre-rRNA/ACTB, 18S rRNA/45S pre-rRNA and 28S rRNA/45S pre-rRNA ratios in siCtl treated cells were normalized to 1, respectively. Data were expressed as mean ± SEM from 3 independent samples per condition (N=3) for D-F. *p<0.05 and **p<0.01 by Kruskal–Wallis test and Dunn’s multiple comparison test. (G-I) 45S pre-rRNA/ACTB, 18S rRNA/45S pre-rRNA and 28S rRNA/45S pre-rRNA ratios in human control, HD and SCA2 postmortem cerebella. 45S pre-rRNA/ACTB, 18S rRNA/45S pre-rRNA and 28S

rRNA/45S pre-rRNA ratios in Ctl group were normalized to 1, respectively. Data were expressed as mean $\pm$ SEM from N=3 (Ctl), 4 (HD) and 5 (SCA2) individual patient cerebella samples.

* $p < 0.05$ by Kruskal–Wallis test and Dunn’s multiple comparison test.

Table 1. Human control and patient brain information.

Disease	Case ID	<i>ATXN2</i> alleles	<i>HTT</i> alleles	Age of death	Age of onset	Gender	PMI (hr)
Control	201	22/22	20/25	62	N/A	M	14
	219	22/22	17/18	35	N/A	F	8
	249	22/22	18/18	49	N/A	M	12
SCA2	K1	22/37	17/18	72	40	F	6
	H1	22/38	15/17	74	60	F	19
	K2	22/41	14/17	49	26	M	24
	K3	22/41	18/23	55	35	F	24
	M1	22/44	17/22	43	30	M	23
HD	791	22/22	36/43	56	38	M	10
	172	22/25	18/45	63	N/A	M	8.5
	372	22/22	15/47	62	34	M	18
	903	22/22	18/45	59	38	M	7

Acknowledgments

We would like to acknowledge support for the statistical analysis from the National Center for Research Resources and the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health through grant 1UL1TR001079. We thank Dr. Laura Ranum for the kind gift of the A8(*KKQ_{EXP})-3Tf1 construct. We thank Dr. Arnulf Koeppen, for providing frozen brain samples of three SCA2 patients. We thank Dr. Olga Pletnikova for providing a frozen brain sample of one SCA2 patient. We thank Dr. Shanshan Zhu for technical assistance regarding confocal imaging. We thank Kathryn A. Carson, Sc.M. for the advice on statistical analysis.

Author contributions

D.D.R. and P.P.L conceived the study, oversaw the project, and designed the experiments; P.P.L., R.M., H.F., X.S., N.A., J.J., L.M., E.H., and D.D.R. carried out the experiments and analyzed data; H.Y.E.C., C.A.R., S.M.P., R.L.M., and S.W. provided fundamental reagents and intellectual contribution; P.P.L., R.M., R.L.M., S.W., and D.D.R. wrote the manuscript. D.D.R. contributed to this work prior to her current position. All the authors had final approval of the submitted version.

References

1. Pulst, S. M. in *GeneReviews*((R)) (ed Adam, M. P. et al.) (University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved, Seattle (WA), 1993).
2. Geschwind, D. H., Perlman, S., Figueroa, C. P., Treiman, L. J. & Pulst, S. M. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. *Am. J. Hum. Genet.* **60**, 842-850 (1997).
3. Cancel, G. *et al.* Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. *Hum. Mol. Genet.* **6**, 709-715 (1997).
4. Rottnek, M. *et al.* Schizophrenia in a patient with spinocerebellar ataxia 2: coincidence of two disorders or a neurodegenerative disease presenting with psychosis? *Am. J. Psychiatry* **165**, 964-967 (2008).
5. Chen, K. H., Lin, C. H. & Wu, R. M. Psychotic-affective symptoms and multiple system atrophy expand phenotypes of spinocerebellar ataxia type 2. *BMJ Case Rep.* **2012**, 10.1136/bcr.10.2011.5061 (2012).
6. Riess, O. *et al.* SCA2 trinucleotide expansion in German SCA patients. *Neurogenetics* **1**, 59-64 (1997).
7. Lorenzetti, D., Bohlega, S. & Zoghbi, H. Y. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. *Neurology* **49**, 1009-1013 (1997).
8. Moseley, M. L. *et al.* Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. *Neurology* **51**, 1666-1671 (1998).
9. Cruz-Marino, T. *et al.* SCA2 predictive testing in Cuba: challenging concepts and protocol evolution. *J. Community Genet.* **6**, 265-273 (2015).
10. Velazquez Perez, L. *et al.* Molecular epidemiology of spinocerebellar ataxias in Cuba: insights into SCA2 founder effect in Holguin. *Neurosci. Lett.* **454**, 157-160 (2009).
11. Orozco, G. *et al.* Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological, and biochemical findings. *J. Neurol. Sci.* **93**, 37-50 (1989).
12. Rub, U. *et al.* Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. *Brain* **126**, 2257-2272 (2003).
13. Rub, U. *et al.* Involvement of the cholinergic basal forebrain nuclei in spinocerebellar ataxia type 2 (SCA2). *Neuropathol. Appl. Neurobiol.* **39**, 634-643 (2013).
14. Rub, U. *et al.* Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. *Neuropathol. Appl. Neurobiol.* **31**, 127-140 (2005).

15. Rub, U. *et al.* Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. *Prog. Neurobiol.* **104**, 38-66 (2013).
16. Moretti, P. *et al.* Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy. *Am. J. Med. Genet. A.* **124A**, 392-396 (2004).
17. Giunti, P. *et al.* The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. *Brain* **121** (Pt 3), 459-467 (1998).
18. Pulst, S. M. *et al.* Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. *Nat. Genet.* **14**, 269-276 (1996).
19. Elden, A. C. *et al.* Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* **466**, 1069-1075 (2010).
20. Huynh, D. P., Yang, H. T., Vakharia, H., Nguyen, D. & Pulst, S. M. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. *Hum. Mol. Genet.* **12**, 1485-1496 (2003).
21. Magana, J. J., Velazquez-Perez, L. & Cisneros, B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. *Mol. Neurobiol.* **47**, 90-104 (2013).
22. Hansen, S. T., Meera, P., Otis, T. S. & Pulst, S. M. Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2. *Hum. Mol. Genet.* **22**, 271-283 (2013).
23. Huynh, D. P., Figueroa, K., Hoang, N. & Pulst, S. M. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. *Nat. Genet.* **26**, 44-50 (2000).
24. Dansithong, W. *et al.* Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. *PLoS Genet.* **11**, e1005182 (2015).
25. Thornton, C. A. Myotonic dystrophy. *Neurol. Clin.* **32**, 705-19, viii (2014).
26. Pettersson, O. J., Aagaard, L., Jensen, T. G. & Damgaard, C. K. Molecular mechanisms in DM1 - a focus on foci. *Nucleic Acids Res.* **43**, 2433-2441 (2015).
27. Banez-Coronel, M. *et al.* A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. *PLoS Genet.* **8**, e1002481 (2012).
28. Sun, X. *et al.* Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65. *Sci. Rep.* **5**, 12521 (2015).
29. Rudnicki, D. D. *et al.* Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. *Ann. Neurol.* **61**, 272-282 (2007).

30. Tsoi, H., Lau, C. K., Lau, K. F. & Chan, H. Y. Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases. *Hum. Mol. Genet.* **20**, 3787-3797 (2011).
31. Tsoi, H., Lau, T. C., Tsang, S. Y., Lau, K. F. & Chan, H. Y. CAG expansion induces nucleolar stress in polyglutamine diseases. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 13428-13433 (2012).
32. Li, L. B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in *Drosophila*. *Nature* **453**, 1107-1111 (2008).
33. Moseley, M. L. *et al.* Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. *Nat. Genet.* **38**, 758-769 (2006).
34. Echeverria, G. V. & Cooper, T. A. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. *Brain Res.* **1462**, 100-111 (2012).
35. Krzyzosiak, W. J. *et al.* Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. *Nucleic Acids Res.* **40**, 11-26 (2012).
36. Goodwin, M. & Swanson, M. S. RNA-binding protein misregulation in microsatellite expansion disorders. *Adv. Exp. Med. Biol.* **825**, 353-388 (2014).
37. Cho, D. H. *et al.* Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. *Mol. Cell* **20**, 483-489 (2005).
38. Wilburn, B. *et al.* An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. *Neuron* **70**, 427-440 (2011).
39. Seixas, A. I. *et al.* Loss of junctophilin-3 contributes to Huntington disease-like 2 pathogenesis. *Ann. Neurol.* **71**, 245-257 (2012).
40. Sopher, B. L. *et al.* CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. *Neuron* **70**, 1071-1084 (2011).
41. Chung, D. W., Rudnicki, D. D., Yu, L. & Margolis, R. L. A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. *Hum. Mol. Genet.* **20**, 3467-3477 (2011).
42. Li, P. P. *et al.* ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. *Ann. Neurol.* **80**, 600-615 (2016).
43. Trottier, Y. *et al.* Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. *Nat. Genet.* **10**, 104-110 (1995).
44. Zu, T. *et al.* Non-ATG-initiated translation directed by microsatellite expansions. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 260-265 (2011).

45. Sobczak, K. & Krzyzosiak, W. J. CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts. *J. Biol. Chem.* **280**, 3898-3910 (2005).
46. Rudnicki, D. D., Margolis, R. L., Pearson, C. E. & Krzyzosiak, W. J. Diced triplets expose neurons to RISC. *PLoS Genet.* **8**, e1002545 (2012).
47. Wojciechowska, M. & Krzyzosiak, W. J. CAG repeat RNA as an auxiliary toxic agent in polyglutamine disorders. *RNA Biol.* **8**, 565-571 (2011).
48. Urbanek, M. O. & Krzyzosiak, W. J. RNA FISH for detecting expanded repeats in human diseases. *Methods* **98**, 115-123 (2016).
49. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523-6 (2019).
50. Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* **47**, D607-D613 (2019).
51. Wada, K. *et al.* Dynamics of WD-repeat containing proteins in SSU processome components. *Biochem. Cell Biol.* **92**, 191-199 (2014).
52. Hutchinson, S. A. *et al.* Tbl3 regulates cell cycle length during zebrafish development. *Dev. Biol.* **368**, 261-272 (2012).
53. Zhang, Y. *et al.* ProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projects. *J. Proteomics* **129**, 25-32 (2015).
54. Ross, C. A. & Tabrizi, S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol.* **10**, 83-98 (2011).
55. Sun, X. *et al.* Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. *Hum. Mol. Genet.* **23**, 6302-6317 (2014).
56. Yuan, Y. *et al.* Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. *Nucleic Acids Res.* **35**, 5474-5486 (2007).
57. Hughes, J. M. & Ares, M. Depletion of U3 small nucleolar RNA inhibits cleavage in the 5' external transcribed spacer of yeast pre-ribosomal RNA and impairs formation of 18S ribosomal RNA. *EMBO J.* **10**, 4231-4239 (1991).
58. Haeusler, A. R. *et al.* C9orf72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* **507**, 195-200 (2014).
59. Wang, J. & Tsai, S. Tbl3 encodes a WD40 nucleolar protein with regulatory roles in ribosome biogenesis. *World J Hematol.* **3**, 93-104 (2014).

60. Henras, A. K., Plisson-Chastang, C., O'Donohue, M. F., Chakraborty, A. & Gleizes, P. E. An overview of pre-ribosomal RNA processing in eukaryotes. *Wiley Interdiscip. Rev. RNA* **6**, 225-242 (2015).
61. Aubert, M., O'Donohue, M. F., Lebaron, S. & Gleizes, P. E. Pre-Ribosomal RNA Processing in Human Cells: From Mechanisms to Congenital Diseases. *Biomolecules* **8**, 10.3390/biom8040123 (2018).
62. Gallagher, J. E. *et al.* RNA polymerase I transcription and pre-rRNA processing are linked by specific SSU processome components. *Genes Dev.* **18**, 2506-2517 (2004).
63. Albert, B. *et al.* A ribosome assembly stress response regulates transcription to maintain proteome homeostasis. *Elife* **8**, 10.7554/eLife.45002 (2019).
64. O'Rourke, J. G. *et al.* C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. *Neuron* **88**, 892-901 (2015).
65. Lionnet, T. *et al.* A transgenic mouse for in vivo detection of endogenous labeled mRNA. *Nat. Methods* **8**, 165-170 (2011).
66. Kiliszek, A., Kierzek, R., Krzyzosiak, W. J. & Rypniewski, W. Atomic resolution structure of CAG RNA repeats: structural insights and implications for the trinucleotide repeat expansion diseases. *Nucleic Acids Res.* **38**, 8370-8376 (2010).
67. Tawani, A. & Kumar, A. Structural Insights Reveal the Dynamics of the Repeating r(CAG) Transcript Found in Huntington's Disease (HD) and Spinocerebellar Ataxias (SCAs). *PLoS One* **10**, e0131788 (2015).
68. Ross, C. A. *et al.* Huntington disease: natural history, biomarkers and prospects for therapeutics. *Nat. Rev. Neurol.* **10**, 204-216 (2014).
69. Rees, E. M. *et al.* Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment? *Mov. Disord.* **29**, 1648-1654 (2014).
70. Klionsky, D. J. *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* **8**, 445-544 (2012).
71. Rub, U. *et al.* Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. *Brain Pathol.* **23**, 165-177 (2013).
72. Haeusler, A. R. *et al.* C9orf72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* **507**, 195-200 (2014).

A **B** **C** **D** **E** **F**

A

In vitro transcription of biotinylated RNAs
● biotin

Binding of biotinylated RNAs to streptavidin beads
streptavidin

Binding of proteins to biotinylated RNAs

Elution

Mass spectrometry

B **C** **D**

A **B** **C** **D** **E** **F** **G** **H** **I**

GTGCGTGAAGCCC(CAG)_nCCGCCGCCCGCGGCTGCCAAT

A

O:0008380: RNA splicing
 HSA.8953854: Metabolism of RNA
 O:0022613: ribonucleoprotein complex biogenesis
 O:0034660: ncRNA metabolic process
 O:0043484: regulation of RNA splicing
 ORUM:3055: Nop56p-associated pre-rRNA complex
 O:0048524: positive regulation of viral process
 ORUM:924: Toposome
 HSA.167238: Pausing and recovery of Tat-mediated HIV elongation
 O:0032210: regulation of telomere maintenance via telomerase
 O:0006401: RNA catabolic process
 O:0045815: positive regulation of gene expression, epigenetic
 O:0008033: tRNA processing

B